Exosome diagnostics and therapeutics market to grow by USD 483.18M

The exosome diagnostics and therapeutics market size is set to grow by USD 483.18 million from 2022 to 2027 and register an accelerating CAGR of 21.55%, according to Technavio’s latest market research report estimates. With a focus on identifying dominant industry influencers, Technavio’s reports present a detailed study by way of synthesis and summation of data from multiple sources. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment.

Exosome diagnostics and therapeutics market 2023-2027: Segmentation

• End-user
  • Research and academic institutes
  • Pharmaceutical and biotechnology companies
  • Commercial
• Application
  • Diagnostic
  • Therapeutic
• Geography
  • North America
  • Europe
  • Asia
  • Rest Of World (ROW)

The market share growth by the research and academic institutes segment will be significant during the forecast period. Research and academic institutions play a crucial part in innovation-based, knowledge-driven growth. The future success of these academic institutions highly relies on collaborations between academia, industry, and regulators.

Exosome diagnostics and therapeutics market 2023-2027: Vendor analysis and scope
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. To help businesses improve their market position, the exosome diagnostics and therapeutics market provide a detailed analysis of around 15+ vendors operating in the market. Some of these vendors include Aethlon Medical Inc., Bio-Techne Corp., BioCat GmbH, BioVision Inc., Capricor Therapeutics Inc., Cell Guidance Systems Ltd., Clara Biotech Inc., Evox Therapeutics Ltd., Hologic Inc., JSR Life Sciences LLC, Lonza Group Ltd., Miltenyi Biotec B.V. and Co. KG, Nanosomix Inc., NX PharmaGen Inc., QIAGEN NV, ReNeuron Group plc, Sarepta Therapeutics Inc, Spectris Plc, System Biosciences LLC, and Thermo Fisher Scientific Inc..

Exosome diagnostics and therapeutics market 2023-2027: Market dynamics
Key drivers
The growing research on exosomes for new therapeutics is driving market growth. Exosomes in cardiovascular disease (CVD) have become a main research focus area due to their promising growth potential. Some of the prominent research institutes for exosome therapy in cardiovascular disease include Shanghai Jiao Tong University and Nanjing Medical University. Several research and academic institutions are investing in developing therapeutics by utilizing exosomes. Hence, such a rise in research is expected to drive the exosome diagnostics and therapeutics market growth during the forecast period.

Key trends
The use of advanced technologies in exosome collection is an emerging market trend. One of the main emerging techniques used for exosome isolation is exosome research, which combines immunoaffinity and microfluidic systems approach for more effective exosome collection. Microfluidic devices offer unique functionality that has been impossible with traditional methods due to the great advantages of microfluidic technology. Hence, this innovation of these new technologies is expected to drive the global exosome diagnostics and therapeutics market during the forecast period.

Significant challenge
The strictness in regulatory approval of product launches is a significant challenge to market growth. One of the main challenges in the exosome diagnostics and therapeutics market is surpassing regulatory approval. The approval and commercialization of exosome therapies can only be granted by meeting several stringent regulatory standards. While using exosome therapy products, vendors are forced to comply with stringent regulatory standards for manufacturing processes and validate product safety and efficacy. Hence, such factors are expected to hinder the global exosome diagnostics and therapeutics market during the forecast period. Technavio